These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12831359)

  • 1. Regulatory issues in cellular therapies.
    Gee AP
    Expert Opin Biol Ther; 2003 Jul; 3(4):537-40. PubMed ID: 12831359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
    Yano K; Speidel AT; Yamato M
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The global cell therapy industry continues to rise during the second and third quarters of 2012.
    Mason C; McCall MJ; Culme-Seymour EJ; Suthasan S; Edwards-Parton S; Bonfiglio GA; Reeve BC
    Cell Stem Cell; 2012 Dec; 11(6):735-9. PubMed ID: 23217418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.
    Knoepfler PS; Turner LG
    Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
    Yim R
    Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory issues in cellular therapies.
    Gee AP
    J Cell Biochem Suppl; 2002; 38():104-12. PubMed ID: 12046844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
    Carpenter MK; Couture LA
    Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development for "orphan" diseases.
    Cerami A
    Am J Med; 1978 Sep; 65(3):407-8. PubMed ID: 717413
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Considerations for Oncolytic Viral Therapies: A Regulatory Perspective.
    Liu K
    Clin Pharmacol Ther; 2017 May; 101(5):580-582. PubMed ID: 28130800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA issues guidance on regulation of cell-based products in animals.
    J Am Vet Med Assoc; 2014 Sep; 245(5):474. PubMed ID: 25289407
    [No Abstract]   [Full Text] [Related]  

  • 20. The Current Status of Cell-Based Therapies for Primary Knee Osteoarthritis.
    Vakharia RM; Roche MW; Alcerro JC; Lavernia CJ
    Orthop Clin North Am; 2019 Oct; 50(4):415-423. PubMed ID: 31466658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.